Cipla Limited
CIPLA · Pharma · NSE
₹1,231
Current Market Price
Fair Value (DCF)
₹1,762
Margin of Safety
+43.1%
Updated 4h ago
YieldIQ Score
66/100
Piotroski F-Score
7/9
Economic Moat
Narrow
Confidence
32%
ROE
16.9%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.99 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
21.5%
Return on capital employed
EV / EBITDA
12.7×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
155.9×
EBIT covers interest
Current Ratio
4.25×
Short-term liquidity
Asset Turnover
0.73×
Revenue per ₹ of assets
Revenue CAGR (3Y)
27.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,231.1
Bear case
₹1,059.91
MoS -16.2%
Base case
₹1,762.03
MoS +30.1%
Bull case
₹2,395.64
MoS +48.6%
Ratio Trends
CIPLA · last 8 annual periods
ROE
16.9%
ROCE
24.8%
Operating Margin
—
Debt / Equity
0.01×
PE
22.1×
EV / EBITDA
14.8×
Historical Financials
CIPLA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹13.9K Cr | ₹13.1K Cr | ₹5739 Cr | ₹4037 Cr | ₹27.1K Cr | +18.2% |
| EBITDA | — | ₹4588 Cr | ₹5152 Cr | ₹6824 Cr | ₹7860 Cr | +14.4% |
| EBIT | ₹3396 Cr | ₹3573 Cr | ₹780 Cr | ₹1230 Cr | — | -22.4% |
| PAT | ₹2468 Cr | ₹2958 Cr | ₹522 Cr | ₹1038 Cr | ₹5273 Cr | +20.9% |
| EPS (diluted) | ₹30.57 | ₹33.30 | ₹6.51 | ₹12.15 | — | -20.6% |
| CFO | ₹3460 Cr | ₹2773 Cr | ₹3238 Cr | ₹3727 Cr | ₹5005 Cr | +9.7% |
| CapEx | — | — | — | — | ₹-1548 Cr | — |
| FCF | — | — | — | — | ₹3457 Cr | +0.0% |
| Total Assets | — | ₹27.1K Cr | ₹29.5K Cr | ₹31.1K Cr | ₹37.4K Cr | +8.4% |
| Total Debt | — | — | ₹520 Cr | ₹0.0 Cr | ₹438 Cr | -4.2% |
| Shareholders' Equity | — | — | ₹23.4K Cr | ₹28.0K Cr | ₹31.3K Cr | +7.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
CIPLA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| DRREDDY Dr. Reddy's Laboratories Limited | +73.3% | 63 | Undervalued | 16.8% | 16.8× |
| ZYDUSLIFE Zydus Lifesciences Limited | +47.7% | 45 | Data Limited | 17.2% | — |
| LUPIN Lupin Limited | +16.1% | 37 | Undervalued | 19.0% | — |
| MANKIND MANKIND | — | — | Pending | 13.7% | — |
| AUROPHARMA Aurobindo Pharma Limited | +36.3% | 59 | Undervalued | 10.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹47.50/sh
Last payout
2025-06-27
₹16.00
Peak payout
₹16.00
Trailing yield
1.30%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of CIPLA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for CIPLA →
Compare
Head-to-head with peers
Compare CIPLA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse CIPLANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.